Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 59 of 101, showing 5 Applications out of 505 total, starting on record 291, ending on 295

# Protocol No Study Title Investigator(s) & Site(s)

291.

ECCT/21/06/05   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinantread more
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR-PHRD THIKA PROJECT
 
View

292.

ECCT/21/06/06   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted read more
Principal Investigator(s)
1. Janet Oyieko
Site(s) in Kenya
1. KEMRI CCR-Butere County Hospital Site (Kakamega county)
2. Kenya Medical Research Instituteread more
View

293.

ECCT/21/06/07   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinantread more
Principal Investigator(s)
1. Samuel Ouma Gurrion Ouma
Site(s) in Kenya
1. Kenya Medical Research Institute Kisumu Clinical Research Site (Kisumu county)
2.read more
View

294.

ECCT/21/06/08   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted  read more
Principal Investigator(s)
1. Saleh Mansoor
Site(s) in Kenya
1. Aga Kahn University Nairobi (Nairobi City county)
2. Kenya Medical Research Institute (read more
View

295.

ECCT/21/06/10   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinantread more
Principal Investigator(s)
1. Kishorchandra Narsinh Mandaliya
Site(s) in Kenya
1. Kenya Medical Research Institute (Kisumu county)
2. KEMRI/Walter Reedread more
View